{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:44:24Z","timestamp":1784087064433,"version":"3.55.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To assess the safety and efficacy of sorafenib and sunitinib as first-line treatments for metastatic renal cell carcinoma (mRCC), to provide evidence-based support for clinical decision-making regarding rational drug use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Until May 10, 2023, a comprehensive search was conducted across PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, and Wanfang databases to identify clinical studies comparing sorafenib with sunitinib as first-line treatment for mRCC. The literature was screened, data extracted, and quality evaluated independently by 2 researchers. Meta-analysis was conducted using Revman5.4 software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 3741 patients were enrolled in 20 studies. The meta-analysis results indicated that there were no significant differences in the 2- and 5-year progression-free survival (PFS) and overall survival (OS) rates between the sorafenib and sunitinib groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u2005.05). The disease control rate (DCR) was comparable between the 2 groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u2005.05), while the objective response rate (ORR) was higher in the sunitinib group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.03). However, subgroup analysis revealed no significant differences in ORR, DCR, 2- and 5-year PFS, and OS rates between sorafenib and sunitinib among both Asian populations as well as European and American populations (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u2005.05). In terms of drug-related adverse events, the incidence of grade\u2005\u2265\u20053 hypertension, leukopenia, neutropenia, thrombocytopenia, anemia, nausea and vomiting were significantly lower in the sorafenib group compared to the sunitinib group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In the first-line treatment of mRCC, sorafenib exhibits comparable efficacy to sunitinib but with lower toxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034983","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T14:05:28Z","timestamp":1694181928000},"page":"e34983","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0644-4791","authenticated-orcid":false,"given":"Dailong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology, General Hospital of The Yangtze River Shipping, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Anatomy, College of Basic Medicine, Guilin Medical University, Guilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People\u2019s Hospital, Yichang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlai","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, General Hospital of The Yangtze River Shipping, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of The Yangtze River Shipping, Wuhan, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma.","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update.","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","article-title":"Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).","volume":"26","author":"Launay-Vacher","year":"2015","journal-title":"Ann Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"27044","DOI":"10.18632\/oncotarget.7395","article-title":"Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.","volume":"7","author":"Sheng","year":"2016","journal-title":"Oncotarget"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40880-017-0230-7","article-title":"Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.","volume":"36","author":"Cai","year":"2017","journal-title":"Chin J Cancer"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000346484","article-title":"Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.","volume":"58","author":"Park","year":"2012","journal-title":"Chemotherapy"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1464-410X.2009.08972.x","article-title":"Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.","volume":"105","author":"Choueiri","year":"2010","journal-title":"BJU Int"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/COC.0b013e3181a650a6","article-title":"Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.","volume":"33","author":"La Vine","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2014.07.011","article-title":"Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.","volume":"193","author":"Santoni","year":"2015","journal-title":"J Urol"},{"key":"R16-20250504","first-page":"94","article-title":"To assess the effectiveness and safety of sunitinib malate capsules in managing advanced renal clear cell carcinoma patients.","volume":"8","author":"Zhang","year":"2021","journal-title":"Health Horizon"},{"key":"R17-20250504","first-page":"327","article-title":"Comparison between the efficacy of sunitinib and sorafenib in the first-line therapy on metastatic renal cell carcinoma.","volume":"25","author":"Yao","year":"2018","journal-title":"Chin J Clin Med"},{"key":"R18-20250504","first-page":"8","article-title":"Study on the difference of sunitinib and sorafenib as first-line treatment in advanced renal carcinoma.","volume":"43","author":"Dai","year":"2016","journal-title":"J Int Oncol"},{"key":"R19-20250504","first-page":"53","article-title":"Effects of Sorafenib and Sunitinib first-line treatment on immune function of patients with metastatic renal cell carcinoma.","volume":"29","author":"Feng","year":"2022","journal-title":"J Rare Uncommon Dis"},{"key":"R20-20250504","first-page":"384","article-title":"Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival.","volume":"40","author":"Wen","year":"2018","journal-title":"Chin J Oncol"},{"key":"R21-20250504","first-page":"1665","article-title":"Comparison of the effects of sorafenib and sunitinib in patients with metastatic renal cell carcinoma.","volume":"39","author":"Li","year":"2019","journal-title":"Chin J Hosp Pharm"},{"key":"R22-20250504","first-page":"153","article-title":"Analysis of disease control, survival status and hematological toxicity of sorafenib and shunitinib in the treatment of metastatic renal cell carcinoma.","volume":"108","author":"Liu","year":"2021","journal-title":"Renowned Doct"},{"key":"R23-20250504","first-page":"1467","article-title":"Short-and long-term efficacy of sorafenib and sunitinib for metastatic renal cell carcinoma and the factors influencing the prognosis.","volume":"26","author":"Wang","year":"2019","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clgc.2013.05.002","article-title":"\u201cReal World\u201d treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.","volume":"11","author":"Harrison","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ejca.2013.02.003","article-title":"Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.","volume":"49","author":"Levy","year":"2013","journal-title":"Eur J Cancer"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jgo.2013.04.004","article-title":"Sorafenib and sunitinib for elderly patients with renal cell carcinoma.","volume":"4","author":"Derbel Miled","year":"2013","journal-title":"J Geriatr Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12885-016-3016-4","article-title":"Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Cancer"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/jjco\/hyz127","article-title":"Sunitinib versus sorafenib for patients with advanced renal cell carcinoma with renal impairment before the immune-oncology therapy era.","volume":"49","author":"Takayama","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/jjco\/hyx161","article-title":"Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.","volume":"47","author":"Ishihara","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00432-014-1870-5","article-title":"Height and kidney cancer risk: a meta-analysis of prospective studies.","volume":"141","author":"Liang","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.drup.2023.100929","article-title":"Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers.","volume":"67","author":"Jin","year":"2023","journal-title":"Drug Resist Updat"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"105732","DOI":"10.1016\/j.phrs.2021.105732","article-title":"New frontiers against sorafenib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers.","volume":"170","author":"He","year":"2021","journal-title":"Pharmacol Res"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1634\/theoncologist.2009-0088","article-title":"Sorafenib and sunitinib.","volume":"14","author":"Kim","year":"2009","journal-title":"Oncologist"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3389\/fonc.2019.00479","article-title":"Comparative efficacy, safety, and costs of Sorafenib vs. Sunitinib as first-line therapy for metastatic renal cell carcinoma: a systematic review and meta-analysis.","volume":"9","author":"Deng","year":"2019","journal-title":"Front Oncol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1592\/phco.27.8.1125","article-title":"Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.","volume":"27","author":"Grandinetti","year":"2007","journal-title":"Pharmacotherapy"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:27:28Z","timestamp":1746325648000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":35,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034983","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}